Compare PDLB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | SGHT |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.1M | 309.6M |
| IPO Year | 2021 | 2021 |
| Metric | PDLB | SGHT |
|---|---|---|
| Price | $20.29 | $8.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 63.0K | ★ 206.2K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 28.16 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $28.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.91 | $3.19 |
| 52 Week High | $21.10 | $9.24 |
| Indicator | PDLB | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 56.69 |
| Support Level | $19.66 | $8.00 |
| Resistance Level | $20.81 | $8.80 |
| Average True Range (ATR) | 0.40 | 0.35 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 56.12 | 29.36 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.